Skip to main content Skip to main navigation menu Skip to site footer

Inadequate treatment in a patient with minimal change disease (MCD) nephrotic syndrome: a case report

  • Alifatul Maslachah ,
  • Dana Pramudya ,
  • Pranawa ,
  • Widodo ,
  • Nunuk Mardiana ,
  • Artaria Tjempakasari ,


Introduction: Minimal change disease (MCD) is the cause of primary nephrotic syndrome in about 90% of children but is rare in adults and only found in about 10% to 15% of adults. Adequate steroid therapy can lead to complete remission in more than 80% of adults with MCD nephrotic syndrome. This study aimed to report a case of an adult patient with nephrotic syndrome with renal biopsy results of MCD and her clinical improvement after adequate therapy with glucocorticoids.

Case Presentation: We report a case of a female patient, 35 years old, who complained of swelling all over the body 3 months before admission. Previously, the patient was diagnosed with nephrotic syndrome on December 2020 and received oral steroid therapy that had been tapered down early, which caused the clinical symptoms to recur. The patient underwent a kidney biopsy, and MCD was found on histopathological examination. The patient received supportive therapy and resumed steroid therapy with adequate dosage. On the six-month follow-up, the patient was in complete remission.

Conclusion: MCD is a nephrotic syndrome with a good prognosis, and 80% of patients will respond to adequate therapy. Our patient's previous medical history was re-evaluated, and concluded that the previous patient had received inadequate therapy. The patient has now reached a state of complete remission. This case highlighted the importance of adequate therapy in managing nephrotic syndrome.


  1. Maharani ARK, Mardiana N. A pregnancy with nephrotic syndrome: A rare case. Vol. 99, International journal of surgery case reports. Netherlands; 2022. p. 107707.
  2. Samudra D, Widodo, Mardiana N, Tjempakasari A, Pranawa, Aditiawardana, et al. Nephrotic Syndrome with Focal Segmental Glomerulosclerosis Histological Feature: A Case Report. Pharmacogn J. 2022;14:459–61.
  3. Thamrin H, Sutjahjo A, Pranoto A, Soelistijo SA. Association of Metabolic Syndrome with Albuminuria in Diabetes Mellitus Type 2. Biomol Heal Sci J. 2019;2(2 SE-Original Article):82–8. Available from:
  4. Ifadha RT, Prasetyo RV, Kahar H. Correlation Between Duration of Illness and Quality of Life in Pediatric Patients with Nephrotic Syndrome at Dr. Soetomo General Hospital, Surabaya, Indonesia – A Cross-Sectional Study. Rwanda Med J. 2021;78(1):16–22.
  5. Nishi S, Ubara Y, Utsunomiya Y, Okada K, Obata Y, Kai H, et al. Evidence-based clinical practice guidelines for nephrotic syndrome 2014. Clin Exp Nephrol. 2016;20(3):342–70.
  6. Vivarelli M, Massella L, Ruggiero B, Emma F. Minimal Change Disease. StatPearls [Internet]. 2021;
  7. Subandiyah K, Khanifa H, Kardani AK. Effect of corticosteroid and vitamin D3 as combined therapy on 25 (OH) vitamin D serum level and regulatory T (TReg) cells population in children with idiopathic nephrotic syndrome. Bali Med J. 2018;7(3 SE-ORIGINAL ARTICLE). Available from:
  8. Königshausen E, Sellin L. Recent Treatment Advances and New Trials in Adult Nephrotic Syndrome. Biomed Res Int. 2017;2017.
  9. Rovin BH, Adler SG, Barratt J, Bridoux F, Burdge KA, Chan TM, et al. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021;100(4):S1–276.
  10. Cattran DC, Feehally J, Cook HT, Liu ZH, Fervenza FC, Mezzano SA, et al. Kidney disease: Improving global outcomes (KDIGO) glomerulonephritis work group. KDIGO clinical practice guideline for glomerulonephritis. Kidney Int Suppl. 2012;2(2):139–274.
  11. Kodner C. Diagnosis and management of nephrotic syndrome in adults. Am Fam Physician. 2016;93(6):479–85.
  12. Sudihardjo W, Prasetyo RV, Umijati S. Clinical profile of children with steroid-sensitive idiopathic nephrotic syndrome relapsing in the first year at dr. soetomo hospital, surabaya. Folia Medica Indones. 2012;48(4):180–5.
  13. Utamiati A, Purnama SW, Roesyanto ID. Relationship of proteinuria severity with Xerosis Cutis in children with Nephrotic Syndrome at the Haji Adam Malik Hospital. Bali Med J. 2020;9(3 SE-ORIGINAL ARTICLE):836–9. Available from:
  14. Moorthy A V, Ozer BH, Oberley TD, Zhong W. Glomerular Disease. In: Pathophysiology of Kidney Disease and Hypertension. Saunders/Elsevier; 2009. p. 89-105.
  15. Mahalingasivam V, Booth J, Sheaff M, Yaqoob M. Nephrotic syndrome in adults. Acute Med. 2018;17(1):36–43.
  16. Clement LC, Macé C, Avila-Casado C, Joles JA, Kersten S, Chugh SS. Circulating angiopoietin-like 4 links proteinuria with hypertriglyceridemia in nephrotic syndrome. Nat Med. 2014;20(1):37–46.
  17. Hull RP, Goldsmith DJA. Nephrotic syndrome in adults. Bmj. 2008;336(7654):1185–9.
  18. Topham PS, Chen Y. Renal Biopsy. In: Comprehensive Clinical Nephrology. Elsevier Health Sciences; 2014. p. 72–9.
  19. Luciano RL, Moeckel GW. Update on the Native Kidney Biopsy: Core Curriculum 2019. Am J Kidney Dis. 2019;73(3):404–15.
  20. Canetta PAA, Radhakrishnan J. The Evidence-Based Approach to Adult-Onset Idiopathic Nephrotic Syndrome. Front Pediatr. 2015;3(September):1–8.
  21. Fiorentino M, Pisano A. Renal Biopsy in 2015 – From Epidemiology to Evidence-Based Indications. 2016;1–19.
  22. Kong X, Yuan H, Fan J, Li Z, Wu T, Jiang L. Lipid-lowering agents for nephrotic syndrome. Cochrane Database Syst Rev. 2013;2013(12).
  23. Noer MS. Long versus standard initial steroid therapy for children with idiopathic nephrotic syndrome. Folia Medica Indones. 2005;41(3):205–11.
  24. Hogan J, Radhakrishnan J. The treatment of minimal change disease in adults. J Am Soc Nephrol. 2013;24(5):702–11.

How to Cite

Maslachah, A., Pramudya, D., Pranawa, Widodo, Mardiana, N., & Tjempakasari, A. (2023). Inadequate treatment in a patient with minimal change disease (MCD) nephrotic syndrome: a case report. Bali Medical Journal, 12(2), 2026–2029.